Atria Wealth Solutions Inc. Buys 2,674 Shares of DexCom, Inc. (NASDAQ:DXCM)

Atria Wealth Solutions Inc. boosted its stake in DexCom, Inc. (NASDAQ:DXCM) by 73.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 6,290 shares of the medical device company’s stock after purchasing an additional 2,674 shares during the quarter. Atria Wealth Solutions Inc.’s holdings in DexCom were worth $781,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also added to or reduced their stakes in the company. Commonwealth Equity Services LLC grew its stake in DexCom by 1.5% during the third quarter. Commonwealth Equity Services LLC now owns 43,769 shares of the medical device company’s stock valued at $4,084,000 after acquiring an additional 635 shares in the last quarter. Cambridge Investment Research Advisors Inc. grew its position in shares of DexCom by 24.6% during the 3rd quarter. Cambridge Investment Research Advisors Inc. now owns 26,463 shares of the medical device company’s stock valued at $2,469,000 after purchasing an additional 5,222 shares in the last quarter. FinTrust Capital Advisors LLC increased its holdings in shares of DexCom by 139.3% in the third quarter. FinTrust Capital Advisors LLC now owns 536 shares of the medical device company’s stock worth $50,000 after purchasing an additional 312 shares during the period. Raymond James Financial Services Advisors Inc. raised its position in shares of DexCom by 12.0% in the third quarter. Raymond James Financial Services Advisors Inc. now owns 154,335 shares of the medical device company’s stock worth $14,399,000 after buying an additional 16,504 shares in the last quarter. Finally, Stratos Wealth Partners LTD. boosted its stake in DexCom by 12.0% during the third quarter. Stratos Wealth Partners LTD. now owns 2,962 shares of the medical device company’s stock valued at $276,000 after buying an additional 318 shares during the period. Hedge funds and other institutional investors own 97.75% of the company’s stock.

DexCom Trading Up 1.4 %

NASDAQ DXCM opened at $128.37 on Friday. The stock has a 50-day moving average of $132.11 and a 200-day moving average of $119.96. The company has a current ratio of 2.90, a quick ratio of 2.53 and a debt-to-equity ratio of 1.08. DexCom, Inc. has a 1-year low of $74.75 and a 1-year high of $142.00. The firm has a market cap of $51.05 billion, a PE ratio of 82.82, a price-to-earnings-growth ratio of 2.15 and a beta of 1.23.

DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Thursday, April 25th. The medical device company reported $0.32 earnings per share for the quarter, beating analysts’ consensus estimates of $0.27 by $0.05. DexCom had a return on equity of 31.01% and a net margin of 16.82%. The firm had revenue of $921.00 million during the quarter, compared to analyst estimates of $911.20 million. As a group, sell-side analysts forecast that DexCom, Inc. will post 1.77 EPS for the current year.

Insiders Place Their Bets

In other news, COO Jacob Steven Leach sold 14,639 shares of the stock in a transaction dated Tuesday, March 12th. The shares were sold at an average price of $134.41, for a total transaction of $1,967,627.99. Following the completion of the sale, the chief operating officer now directly owns 273,913 shares in the company, valued at $36,816,646.33. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In related news, COO Jacob Steven Leach sold 14,639 shares of the company’s stock in a transaction that occurred on Tuesday, March 12th. The stock was sold at an average price of $134.41, for a total transaction of $1,967,627.99. Following the completion of the transaction, the chief operating officer now owns 273,913 shares in the company, valued at $36,816,646.33. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP Michael Jon Brown sold 629 shares of the firm’s stock in a transaction on Tuesday, April 30th. The stock was sold at an average price of $126.25, for a total value of $79,411.25. Following the completion of the sale, the executive vice president now directly owns 68,212 shares of the company’s stock, valued at approximately $8,611,765. The disclosure for this sale can be found here. Insiders have sold a total of 190,004 shares of company stock valued at $25,610,270 in the last quarter. Insiders own 0.41% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the company. Canaccord Genuity Group upped their target price on DexCom from $144.00 to $145.00 and gave the stock a “buy” rating in a research note on Friday, April 26th. UBS Group raised their target price on shares of DexCom from $153.00 to $163.00 and gave the company a “buy” rating in a research note on Wednesday, April 10th. Raymond James boosted their price target on shares of DexCom from $151.00 to $160.00 and gave the stock a “strong-buy” rating in a research note on Friday, April 26th. Royal Bank of Canada began coverage on shares of DexCom in a research report on Tuesday, March 12th. They set an “outperform” rating and a $165.00 price objective on the stock. Finally, StockNews.com upgraded shares of DexCom from a “hold” rating to a “buy” rating in a research report on Wednesday. Two research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $141.67.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.